CAS NO:329-89-5 6-Aminonicotinamide
CAS NO:329-89-5 6-Aminonicotinamide
CAS NO:329-89-5 6-Aminonicotinamide
CAS NO:329-89-5 6-Aminonicotinamide
CAS NO:329-89-5 6-Aminonicotinamide
+
  • CAS NO:329-89-5 6-Aminonicotinamide
  • CAS NO:329-89-5 6-Aminonicotinamide
  • CAS NO:329-89-5 6-Aminonicotinamide
  • CAS NO:329-89-5 6-Aminonicotinamide
  • CAS NO:329-89-5 6-Aminonicotinamide

CAS NO:329-89-5 6-Aminonicotinamide

CAS NO:329-89-5 NAME:6-Aminonicotinamide MF:C6H7N3O MW:137.14 EINECS:206-349-7 Purity:97%+ Appearance:White to Light yellow powder COA:Provide

Categories:

Life Science Chemicals

Pharmaceutical Intermediates

Product introduction

PRODUCT NAME 6-Aminonicotinamide
CAS NO 329-89-5
MP 245-248 °C (lit.)
BP 251.97°C (rough estimate)
DENSITY 1.2620 (rough estimate)
STORAGE 2-8°C
DELIVERY 2-3DAYS
PACKAGE According client's request

Description of CAS NO:329-89-5 6-Aminonicotinamide

6-Aminonicotinamide is an effective antimetabolite of nicotinamide . It is a competitive inhibitor of NADP+ dependent enzymes, such as glucose 6-phosphate dehydrogenase (G6PD) . It leads to ATP depletion and synergizes with DNA-crosslinking chemotherapy drugs, such as Cisplatin, to kill cancer cells.

 

 


Applications of CAS NO:329-89-5 6-Aminonicotinamide

1)Cancer Treatment: Targeting Metabolic Pathways
6-AN is used to target the pentose phosphate pathway (PPP), which is crucial for cancer cell proliferation.

2)Induction of Oxidative Stress
Treatment with 6-AN enhances oxidative stress in cancer cells.

3)Endoplasmic Reticulum Stress Modulation
6-AN affects the endoplasmic reticulum (ER) stress pathways. By inducing ER stress, 6-AN can reduce cell proliferation and govern cellular apoptosis, which is a beneficial effect in cancer therapy

Future Directions
Research is currently being conducted to explore the role of the pentose phosphate pathway in diseases like cancer and the potential of 6-Aminonicotinamide as a therapeutic agent   . The efficient use of metabolic inhibitors like 6-Aminonicotinamide could be a clinically promising therapeutic scheme.

Key words:

Related Products

Related Products

Inquiry

SUBMIT